eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2022
vol. 24
 
Share:
Share:
abstract:
Original paper

Attitudes of family medicine residents in Ankara towards COVID-19 vaccines administered in Turkey: a descriptive, cross-sectional study

Hüsna Sarıca Çevik
1
,
Rana Baykan
2
,
Ayşe Gülsen Ceyhun Peker
2
,
Selda Tekiner
2

  1. Çankaya District Health Directorate, Ankara, Turkey
  2. Family Medicine Department, Ankara University Medical School, Ankara, Turkey
Family Medicine & Primary Care Review 2022; 24(2): 156–161
Online publish date: 2022/06/30
View full text Get citation
 
PlumX metrics:
Introduction
The difficulty of accessing accurate information during the COVID-19 pandemic resulted in many questions being asked to family physicians about vaccination. Objectives. The aim of this study was to determine the attitudes of Family Medicine (FM) residents in Ankara about the inactivated and mRNA COVID-19 vaccines being administered in Turkey.

Material and methods
An anonymous online survey was distributed to FM residents between 22.05.2021–06.06.2021. Information on socio-demographic data and residents’ attitudes towards COVID-19 vaccines administered in Turkey were evaluated.

Results
11.1% of the participants were not vaccinated for the following reasons: having positive Anti-Spike antibody values, thinking that there had not been enough studies on vaccines, vaccine safety concerns, belief that innate immunity would be more protective, pregnancy, breastfeeding or not believing in the protection of the vaccine. While 12.2% of the participants recommended Sinovac-CoronaVac, 23.7% recommended Pfizer/BioNTech, and 63.3% stated that they would evaluate the patient and make recommendations. Most of the participants stated that they thought the Pfizer/BioNTech is more protective against new variants (70.4%), more effective and produces a higher antibody response (84.2%) and provides longer-term protection (74.8%). However, 74.1% of the participants stated that they thought Sinovac-CoronaVac is safer. Sinovac-CoronaVac was recommended to patients with a history of allergic reaction/anaphylaxis (69.8%), autoimmune diseases (60.4%), oncology/chemotherapy patients (49.6%), immunosuppressed patients (49.6) and lactating women (44.6%).

Conclusions
In some case-basis recommendations, it was seen that the residents showed a traditionalist approach. Informing individuals based on scientific information on the safety and effectiveness of the COVID-19 vaccines by family physicians is crucial.

keywords:

SARS-CoV-2, pandemics, primary health care, COVID-19 vaccines, BNT162 vaccine, SARS-CoV-2 inactivated vaccines

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.